view document PDF

USE OF NONINVASIVE RHD GENOTYPING
FOR THE Rh NEGATIVE NON-SENSITIZED MOM*

Mom’s Phenotype

Confirm Mom’s Rh
Genotype using her DNA
 

Establish the presence or absence of circulating cell free fetal nucleic acids in mom’s plasma, which in turn determines the presence or absence of SRY (Y chromosome marker), RHD and PSI (Ψ) alleles.
 

Women who appear
serologically Rh negative
but are genotypically
RH positive are not eligible
for noninvasive RHD testing.

Male Fetus
Rh Positive

Male Fetus Rh Negative

Female Fetus Rh Positive

Request 2nd
Sample

Treat Mom with 28 week RhD immunoglobulin

Routine OB/GYN care without administering
RhD
immunoglobulin

Treat Mom with 28 week RhD immunoglobulin

Probable
Female Fetus
Rh Negative**

Treat Mom with
28 week
RhD immunoglobulin

*RHD genotyping can also be useful for the Rh sensitized mom. When the fetus is found to be Rh positive, then careful surveillance for the development of hemolytic disease is warranted, and if the fetus is Rh negative, then it is not in danger of developing hemolytic disease.

**Due to the nature of this testing, these patients will still require a 28 week RhD immunoglobulin shot. Additional markers are currently being evaluated that will allow for a more definitive diagnosis in this group of patients.

SEQureDx^TM is a trademark of Sequenom^®, Inc., used under license from Sequenom-2.  Use of the technology,  covered by US Patent 6,258,540, is sublicensed to LENETIX^® by Sequenom^® Inc., the exclusive licensee. “This service is performed pursuant to an agreement with Roche Molecular Systems, Inc.”

view flowchart document PDF

view entire brochure PDF

Tel: 516-320-6370  • Fax: 516-248-4436
Office Hours: Monday - Friday 9:00 am - 5:00pm -
Call for RUSH, late night and Weekend by Appointment

www.lenetix.com  • testing@lenetix.com
  •  174 Mineola Blvd. •  Suite #1  • Mineola, NY 11501  •